Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-06-03T00:14:15.862Z Has data issue: false hasContentIssue false
  • English
  • Français

Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series

Published online by Cambridge University Press:  22 March 2023

J J Y Yeo Open the ORCID record for J J Y Yeo [Opens in a new window] ,
K Stewart ,
P Maniam ,
S Arman ,
D Srinivasan ,
L Wall ,
M MacNeill ,
M Strachan  and
I Nixon
J J Y Yeo*
Affiliation:
Department of Head and Neck Surgery, St John's Hospital at Howden, Livingston, UK
K Stewart
Affiliation:
Department of Head and Neck Surgery, St John's Hospital at Howden, Livingston, UK
P Maniam
Affiliation:
Department of Head and Neck Surgery, St John's Hospital at Howden, Livingston, UK
S Arman
Affiliation:
Department of Head and Neck Surgery, St John's Hospital at Howden, Livingston, UK
D Srinivasan
Affiliation:
Department of Oncology, Western General Hospital, Edinburgh, UK
L Wall
Affiliation:
Department of Oncology, Western General Hospital, Edinburgh, UK
M MacNeill
Affiliation:
Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK
M Strachan
Affiliation:
Metabolic Unit, Western General Hospital, Edinburgh, UK
I Nixon
Affiliation:
Department of Head and Neck Surgery, St John's Hospital at Howden, Livingston, UK
*
Corresponding author: Dr JJY Yeo; Email: justinjuiyuanyeo@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Primary surgical resection remains the mainstay of management in locally advanced differentiated thyroid cancer. Tyrosine kinase inhibitors have recently shown promising results in patients with recurrent locally advanced differentiated thyroid cancer. This study discussed four patients with locally advanced differentiated thyroid cancer managed with tyrosine kinase inhibitors used prior to surgery in the ‘neoadjuvant’ setting.

Method

Prospective data collection through a local thyroid database from February 2016 identified four patients with locally advanced differentiated thyroid cancer unsuitable for primary surgical resection commenced on neoadjuvant tyrosine kinase inhibitor therapy.

Results

All cases had T4a disease at presentation. Three cases tolerated tyrosine kinase inhibitor therapy for more than 14 months while the last case failed to tolerate treatment at 1 month. All patients subsequently underwent total thyroidectomy to facilitate adjuvant radioactive iodine treatment. Disease-specific survival remains at 100 per cent currently (range, 29–75 months).

Conclusion

Neoadjuvant tyrosine kinase inhibitors in locally advanced differentiated thyroid cancer can be effective in reducing primary tumour extent to potentially facilitate a more limited surgical resection for local disease control.

Keywords

Thyroid neoplasmscarcinoma, papillarytreatment outcometyrosine protein kinase inhibitorsantineoplastic agents
Type
Main Article
Information
The Journal of Laryngology & Otology , Volume 137 , Issue 11 , November 2023 , pp. 1237 - 1243
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr J J Y Yeo takes responsibility for the integrity of the content of the paper

Presented at the British Association of Endocrine and Thyroid Surgeons meeting, 8 October 2021, Leeds, UK, and at the European Society of Surgical Oncology meeting, 20 October 2022, Bordeaux, France.

References

National Cancer Institute. Surveillance epidemiology and end results program: seer stat facts: thyroid cancer. In: http://seer.cancer.gov/statfacts/html/thyro.html [8 January 2022]Google Scholar
Davies, L, Welch, HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:2164–7CrossRefGoogle ScholarPubMed
Elisei, R, Molinaro, E, Agate, L, Masserini, L, Ceccarelli, C, Lippi, F et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95:1516–27CrossRefGoogle Scholar
Chaar, M, Kamta, J, Ait-Oudhia, S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther 2018;11:6227–37CrossRefGoogle ScholarPubMed
Brose, MS, Nutting, CM, Jarzab, B, Elisei, R, Siena, S, Bastholt, L et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319–28CrossRefGoogle ScholarPubMed
Shlumberger, M, Tahara, M, Wirth, LJ, Robinson, B, Brose, MS, Elisei, R et al. A phase 3, mulitcenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131-I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32:18Google Scholar
Stewart, KE, Strachan, MWJ, Srinivasan, D, MacNeill, M, Wall, L, Nixon, IJ: Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur Thyroid J 2019;8:102–7CrossRefGoogle ScholarPubMed
Megwalu, UC, Orloff, LA, Ma, Y. Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer. Head Neck 2019;41:1719–24CrossRefGoogle ScholarPubMed
Tufano, RP, Clayman, G, Heller, KS, Inabnet, WB, Kebebew, E, Shaha, A et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid 2015;25:15–27CrossRefGoogle ScholarPubMed
Oh, JM, Kalimuthu, S, Gangadaran, P, Baek, SH, Zhu, L, Lee, HW et al. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system. Oncotarget 2018;9:7075–87CrossRefGoogle ScholarPubMed